Carta Acquires Accelex to Deliver AI-Powered Data Automation and Transparency for Capital Allocators
2.10.2025 15:01:00 CEST | Business Wire | Press release
Acquisition unlocks powerful analytics for limited partners by transforming investment documents and fund data into actionable, AI-enabled insights into their alternative investments portfolio and performance
Carta, the software platform purpose-built for private capital, today announced it has acquired Accelex, the AI-powered data automation platform focused on alternative investments for institutional limited partners (LPs). The acquisition deepens Carta’s commitment to serving its network of more than 125,000 Limited Partners by offering unprecedented clarity into the drivers of alternative asset portfolio performance. With our new LP Portfolio Analytics suite powered by Accelex, Carta will enable institutional LPs to automate document collection, scale data extraction, and accelerate portfolio analysis across their entire portfolio from multiple sources.
“Institutional LPs are core to Carta’s network. Integrating Accelex advances our vision of a connected, transparent platform where LPs, GPs, and portfolio companies benefit from shared data and seamless reporting,” said Henry Ward, Chief Executive Officer, Carta. “LPs don’t just need data—they need actionable analytics. With Accelex, allocators gain instant visibility into what’s driving returns across their alternative portfolios, enabling smarter, faster decisions backed by structured, audit-ready information.”
LPs have historically faced inefficient data collection, error-prone manual processes, and disjointed reporting—especially for alternative investments such as private equity and venture capital. By combining Carta’s connected platform with Accelex’s AI-powered LP Portfolio Analytics, LPs experience a new era of automation and reliability with features that include:
- Automated document collection and KPI extraction, including investor portals, emails, and document transfer tools—saving analysts hours each week and surfacing data locked in unstructured files.
- AI-powered accuracy that eliminates human error, flags irregularities for review, and produces structured, auditable outputs.
- Customizable workflows and a complete audit trail, ensuring data extraction aligns with each LP’s internal processes while providing instant tracebacks to the source.
- Analysis-ready dashboards that highlight KPIs such as IRR, MOIC, and EBITDA, and support portfolio lookthroughs, exposure analysis, and cohort comparisons.
Accelex has earned the trust of some of the world’s most demanding capital allocators by providing asset-level transparency and analytics for the industry’s most complex portfolios. Their capability to integrate data from the portfolio company to the asset allocator represents a significant advancement in data connectivity — a welcome addition given traditional fund administrators and platforms still rely on manual processes.
“Joining Carta represents an exciting next chapter for Accelex,” said Franck Vialaron, Chief Executive Officer and founder, Accelex. “From day one, our mission has been to equip investors with the tools and insights they need to tackle complexity, make informed decisions, and achieve their investment goals. Now with Carta, we can further that mission, delivering even greater value to ensure our clients not only keep pace with the market, but stay ahead of it.”
Over the coming months, Accelex’s technology will be fully integrated into Carta’s ecosystem, ensuring seamless migration for current Accelex clients while providing immediate, secure access to Carta’s Fund Administration platform, tax solutions, and world-class support. As a result, LPs will benefit from connected reporting and workflow automation across all their alternative allocations, gaining a true 360° portfolio view that includes assets administered both on and off Carta.
To learn more, visit the blog carta.com/blog/accelex-acquisition. To learn more about Carta, follow us on LinkedIn, X, Instagram, Youtube, or visit carta.com
About Carta
Carta connects founders, investors, and limited partners through world-class software purpose-built for everyone in venture capital and private equity. Carta's world-class fund administration platform supports 9,000+ funds and SPVs representing over $185B in assets under administration on fund administration, SPV formation, and more. Trusted by more than 65,000 companies, Carta helps private businesses in over 160 countries manage their cap tables, valuations, taxes, equity programs, compensation, and more. Carta has been included on the Fortune Best Large Workplaces in Financial Services and Insurance list, Forbes' list of the World's Best Cloud Companies, Fast Company's Most Innovative list, and Inc. 's Fastest-Growing Private Companies list. For more information, visit carta.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20251002006853/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom